MCID: LCR012
MIFTS: 24

Lacrimal System Cancer

Categories: Neuronal diseases, Cancer diseases

Aliases & Classifications for Lacrimal System Cancer

MalaCards integrated aliases for Lacrimal System Cancer:

Name: Lacrimal System Cancer 12 14
Neoplasm of Lacrimal System 12 69
Tumor of the Lacrimal System 12
Lacrimal System Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:292
NCIt 47 C5102
SNOMED-CT 64 416510003
UMLS 69 C1334361

Summaries for Lacrimal System Cancer

MalaCards based summary : Lacrimal System Cancer, also known as neoplasm of lacrimal system, is related to vitamin b12 deficiency and anuria. An important gene associated with Lacrimal System Cancer is TENM3 (Teneurin Transmembrane Protein 3), and among its related pathways/superpathways are One carbon pool by folate and Glycine, serine and threonine metabolism. The drugs Acetylcholine and rituximab have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, bone and thyroid.

Related Diseases for Lacrimal System Cancer

Diseases related to Lacrimal System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 vitamin b12 deficiency 9.8 PSPH SHMT1
2 anuria 9.0 BPTF PSPH SHMT1
3 severe acute respiratory syndrome 7.9 BPTF MAML2 PSPH TENM1 TENM3
4 lacrimal gland carcinoma 7.5 BPTF MAML2 PSPH SHMT1 TENM1 TENM3

Symptoms & Phenotypes for Lacrimal System Cancer

Drugs & Therapeutics for Lacrimal System Cancer

Drugs for Lacrimal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 2 51-84-3 187
2
rituximab Approved Phase 2 174722-31-7 10201696
3
Ephedrine Approved Phase 2 299-42-3 9294
4
Pseudoephedrine Approved Phase 2 90-82-4 7028
5
belimumab Approved Phase 2 356547-88-1 5957 10451420
6
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
7 Anti-Infective Agents Phase 2
8 glucocorticoids Phase 2,Phase 1
9 abobotulinumtoxinA Phase 2
10 Cholinergic Agents Phase 2
11 Neuromuscular Agents Phase 2
12 Neurotransmitter Agents Phase 2
13 Hormone Antagonists Phase 2,Phase 1
14 onabotulinumtoxinA Phase 2
15 Hormones Phase 2,Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
17 Peripheral Nervous System Agents Phase 2,Phase 1
18 Anti-Inflammatory Agents Phase 2,Phase 1
19 Autonomic Agents Phase 2,Phase 1
20 Antimitotic Agents Phase 2,Phase 1
21 Botulinum Toxins Phase 2
22 Botulinum Toxins, Type A Phase 2
23 Respiratory System Agents Phase 2
24 Nasal Decongestants Phase 2
25 Tetrahydrozoline Phase 2
26 Ophthalmic Solutions Phase 2
27 Vasoconstrictor Agents Phase 2
28 Pharmaceutical Solutions Phase 2
29 Immunosuppressive Agents Phase 2
30 Antirheumatic Agents Phase 2
31
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
32 Dexamethasone acetate Phase 1 1177-87-3
33
protease inhibitors Phase 1
34 Gastrointestinal Agents Phase 1
35 HIV Protease Inhibitors Phase 1
36 Antiemetics Phase 1
37 BB 1101 Phase 1
38 Antineoplastic Agents, Hormonal Phase 1
39
Procaine Approved, Investigational, Vet_approved 59-46-1 4914
40
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
41
Cholecalciferol Approved, Nutraceutical 67-97-0 6221 10883523 5280795
42
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
43
Iodine Investigational 7553-56-2 807
44 cadexomer iodine
45
s 1 (combination)
46 Micronutrients
47 Trace Elements
48 Anti-Infective Agents, Local
49 Central Nervous System Depressants
50 Anesthetics

Interventional clinical trials:

(show all 14)

id Name Status NCT ID Phase Drugs
1 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
2 Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora Completed NCT01282541 Phase 2 Botulinum Toxin Type A;Botulinum Toxin Type A
3 Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome Recruiting NCT02631538 Phase 2 Belimumab;Rituximab;Placebo belimumab;Placebo rituximab
4 Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Active, not recruiting NCT01586767 Phase 2
5 Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel Withdrawn NCT00824811 Phase 2 Cyclosporine Eye Drops (Restasis);Lubricant Eye Drops (Refresh Endura™);Fluorometholone Eye Drops (FML Forte®)
6 Prevention of Docetaxel Induced Dacryostenosis Completed NCT00266838 Phase 1 Maxidex; Lacrystat
7 Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma Unknown status NCT01579344 Radioiodine therapy
8 S-1-induced Lacrimal Drainage Obstruction Unknown status NCT01486472 S-1
9 Natural History of Salivary Gland Dysfunction and Sj(SqrRoot)(Delta)Gren s Syndrome Completed NCT00001852
10 Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells Completed NCT00023491
11 Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa Recruiting NCT02386774
12 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
13 The ASSESS National Multi-center Prospective Cohort Recruiting NCT03040583
14 Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL) Active, not recruiting NCT01880463 Omega-3 fatty acids (fish oil);Fish oil placebo

Search NIH Clinical Center for Lacrimal System Cancer

Genetic Tests for Lacrimal System Cancer

Anatomical Context for Lacrimal System Cancer

MalaCards organs/tissues related to Lacrimal System Cancer:

39
Salivary Gland, Bone, Thyroid, Eye

Publications for Lacrimal System Cancer

Variations for Lacrimal System Cancer

Expression for Lacrimal System Cancer

Search GEO for disease gene expression data for Lacrimal System Cancer.

Pathways for Lacrimal System Cancer

GO Terms for Lacrimal System Cancer

Cellular components related to Lacrimal System Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.62 BPTF PSPH

Biological processes related to Lacrimal System Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron development GO:0048666 8.65 TENM3
2 L-serine metabolic process GO:0006563 8.62 PSPH SHMT1

Molecular functions related to Lacrimal System Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 8.92 PSPH SHMT1 TENM1 TENM3

Sources for Lacrimal System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....